Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting ...Middle East

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that two abstracts on the Company's Antibody Radiation Conjugate (ARC) Iomab-B were accepted for oral presentations at the 2020 American Society of Hematology (ASH)...

Read More Details
Finally We wish PressBee provided you with enough information of ( Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting )

Also on site :

• Japan starts deploying Osprey fleet at a new base to beef up southwestern defense
• South Africa seeks US trade deal after Trump’s 30% citrus tariff
• Josh O’Connor Goes Full Cowboy in ‘Rebuilding’ as Director Max Walker-Silverman Takes on Life After the Fires: ‘Loss Often Comes With Love’